United Kingdomoxfordbiotherapeutics.com
None yet. When a new project in the record names OBT as owner, partner or investor, it shows here.
Three Phase III trials will test DLL3-targeting obrixtamig in SCLC and epNEC, and HER2 TKI zongertinib as adjuvant therapy in resectable HER2‑mutant NSCLC.
